Core Viewpoint - The dialogue between Ren Zhengfei and People's Daily highlights Huawei's resilience in the face of external pressures, emphasizing a focus on progress rather than obstacles [1]. Group 1: Discussion on Chips - Ren Zhengfei downplays concerns regarding chip technology, stating that many Chinese companies are making significant strides in this area, and Huawei is one of them [3]. - He acknowledges that Huawei is currently one generation behind the U.S. in single-chip technology but believes that through innovative methods, practical results can be achieved [3]. - Ren emphasizes the potential for Chinese companies in mid-to-low-end chips and highlights the importance of compound semiconductors [3]. Group 2: Importance of Basic Research - Ren stresses the necessity of foundational theoretical research for technological breakthroughs, indicating that without it, China will lag behind the U.S. [5]. - He mentions that Huawei invests approximately 180 billion yuan annually in R&D, with around 60 billion yuan dedicated to basic theoretical research [5]. - The company has made significant advancements in "root technology" and operating system innovation, contributing to the foundation of China's information industry [5]. Group 3: Digital Infrastructure and AI - Huawei has launched a series of products, including Kunpeng processors and Ascend processors, to build a computing ecosystem for general and AI applications [6]. - Ren views artificial intelligence as potentially the last major technological revolution, with China having advantages such as a robust power supply and advanced communication networks [8]. - He believes that the future of the country is promising, with increasing openness leading to progress and the potential for a unified market [8].

上天天基金APP搜索【777】注册即可 领98元券包 ， 优选基金10元起投！限量发放！先到先 得！ 摩根士丹利中国首席股票策略师王滢（Laura Wang）在6月8日发布的研究报告中指出，全 球投资者对中国的情绪改善，相较于过去，他们增配中国的意愿增强，对科技和新消费行业 的信心增强。在中国股票内部，她重申相对更看好港股和ADR（美国存托凭证）的观点。 全球投资者配置意愿增强 上述条件依然成立，其表示，继续偏好港股和ADR。 谈及人民币兑美元汇率，王滢在报告中指出，到2026年底，人民币兑美元较目前或呈现升值 趋势。这背后的主要原因是美元走弱。据摩根士丹利预测，2026年底，美元指数（DXY）点 位将走弱至89（截至记者发稿，美元指数点位为99.03）。期间，主要发达市场货币如欧元 和日元兑美元的升值幅度将超过10%。同期，人民币兑美元也呈现一定幅度的升值。王滢表 示，尽管面临关税压力，但是人民币大幅度贬值或不是中国政策制定者的目标。 首先，受全球多元化需求推动，客户较以往更愿意增加中国股票头寸。"我们接触的大多数全 球投资者都明确表达了重新增加对中国的敞口的兴趣。"她在报告中表示。 王滢表示，截至目前，整 ...

摘要 今天，A股三大指数集体上涨，创业板指涨超1%，有超4000只个股上涨。 1、今天，A股集体上涨，创业板指涨超1%，有超4000只个股上涨。港股恒生科技指数步入技术型牛市。 隔壁港股同样上涨 ， 恒生科技指数4月8日以来累计涨超20%，步入技术型牛市。 2、 创新药板块创历史新高，今天再度领涨，还能涨多久？后市该如何配置？ 3、 上天天基金APP搜索【777】注册即可 领98元券包 ， 优选基金10元起投！限量发放！先到先得！ 真话白话说财经，理财不说违心话 --这是第1361 篇白话财经- - | 107万 | 12 | | --- | --- | | | | | 09:30 | 15:00 | （图片来源：东方财富APP，统计截至2025/6/9，不作投资推荐） 1、消息面刺激板块走强。 分析人士认为， 中美元首通话释放积极信号下关税摩擦影响或进一步减弱，出口链压力缓和下中国增长预期或抬升，继续看好港股， 下半年A股市场 波动率或前低后高，指数有望前稳后升。 | 恒生指数 国企指数 | | --- | | 24181.43 8780.13 5433.23 | | 388.89 1.63% 150.38 ...

以下文章来源于兴证全球基金 ，作者与您相伴的 兴证全球基金 . 投资理财，有温度，有深度，有态度。 两周前 ， 国产创新药对外授权迎来史上首个超过 10亿美元首付款的交易 ， 刷新历史 纪录。 与之呼应的，是创新药这个前几年颇受冷落的领域，今年来不声不响跑出了超 50％的涨幅 （数据来源：恒生港股通创新药指数，Choice ，截至2025/6/5） 。 坦诚地说，创新药投资危险又迷人。一方面，它往往意味着极高的专业壁垒； 但另一面，精准选股后往往又能带来极致锐度。面对今年来如此涨势，市场有 种种困惑 ， 这次创新药为何爆发？中国的创新药产业到底有多强？后续还能 涨多久？ 为此，我们专访了深耕 医药 行业的 兴证全球基金基金经理助理 隋毅 ，聊了 聊 10个大家关心的 问题 。 观点集锦 （创新药板块） 从今年初到现在，是从估值极致压缩到往合理估值去恢复的过程，哪怕到现在为 止，还是有很多质地比较好的创新药公司，在估值合理甚至偏低估的状态。从大的角度判断，现 在这一轮还是在往合理估值走的状态。 回过头看，中国创新药行业从无到有，现在也只过了十年，这十年中国在创新药行业里面做了非 常了不起的事情。如果去评判中国创 ...

今年以来， 创新药 板块表现十分亮眼，尤其是港股 创新药 ，在近期市场震荡中走出了独立 行情。 6月9日， 创新药 板块再度掀起涨停潮，带动医药股全面走强， 海辰药业 、 睿智医药 等多 股20cm封板。 创新药近期为什么表现如此强势？ 华夏基金分析认为，首先是短期热点事件的催化，5月底8家创新药企业的10余款创新药获批 上市，且近期多家创新药企业临床数据优秀；其次是板块热度回升基础夯实，本轮行情开启 主要得益于去年四季度头部创新药企业实现扭亏或盈利增长，以及今年一季度创新药海外授 权金额实现重大突破，行业进入利润兑现期；再次是交易层面的资金流入和估值优势，今年 南向资金累计流入超6600亿港元，再加上医药行业连续多年调整，处于估值洼地，价格比较 吸引人。 短期交易过热？机构意见不一 融通医疗保健的基金经理万民远关于"创新药的泡沫远比上轮CXO泡沫大"的言论，在市场引 发广泛讨论。他随后又更为详细地表达了对创新药的观点，"得益于政策支持、技术突破与国 际化布局，中国创新药产业趋势长期向好，这也是国内医药投资最重要、弹性最大的主线之 一，但随着越来越多的资金涌入创新药上市公司，部分资金可能会忽略创新药企业背后风 ...

Core Viewpoint - The Hong Kong stock market has shown a strong upward trend in 2025, with the Hang Seng Index rising by 16.06%, significantly impacting the A-share market and providing support for its valuation [2][4]. Supply Side - The emergence of phenomenon-level stocks in Hong Kong has led to a widespread profit-making effect, with strong performances from sectors such as new consumption, internet, innovative pharmaceuticals, and dividend stocks [6][8]. - Notable stocks include Lao Pu Gold, Pop Mart, and Mixue Group, which have seen increases of 243.54%, 146.74%, and 81.55% respectively since the beginning of the year [7][8]. - Traditional internet giants like Alibaba and Tencent have rebounded, with increases of 41.87% and 23.37% respectively, driven by advancements in AI technology [10][11]. - The innovative pharmaceutical sector is transitioning from a follower to a leader, with a significant increase in licensing transactions, totaling 519 billion USD in 2024, a 26% year-on-year growth [13]. - The attractiveness of dividend assets in Hong Kong has increased, with a higher dividend yield compared to A-shares, making it appealing for investors seeking stable returns [14]. Liquidity Aspect - Southbound funds and foreign capital have been continuously flowing into the Hong Kong stock market, with 581 billion RMB entering the market in 2025, nearing the historical high of 596.7 billion RMB [19]. - The Hong Kong market is sensitive to changes in overseas liquidity, with a significant increase in daily trading volume by 144% year-on-year in the first four months of 2025 [21]. Product Aspect - The demand for Hong Kong stock funds is rapidly increasing as the market shifts from being an "investment wasteland" to a "hot investment land," with a notable rise in passive investment products [24][26]. - The total scale of ETFs available for investment in Hong Kong stocks reached 178.99 billion RMB by the end of Q1 2025, reflecting a growth of over 45% from the previous quarter [26].

Core Viewpoint - The global investment market in Q3 is characterized by uncertainty, influenced by geopolitical factors and trade policies, presenting both challenges and opportunities for investors [1] Group 1: HSBC Insights - HSBC emphasizes the importance of structural growth in Asia, particularly in China, India, and Singapore, which are expected to mitigate some impacts of the US-China trade war [2] - The bank maintains a diversified investment strategy, adjusting its outlook for US stocks to positive, anticipating a slowdown in economic growth to 1.6% by 2025, while still facing uncertainties [2][3] - HSBC suggests a focus on quality bonds and low-correlation assets, such as gold, to enhance portfolio diversification amid ongoing geopolitical risks [3] Group 2: Standard Chartered Insights - Standard Chartered upgrades its global stock outlook to overweight, citing improved market technical indicators and resilience in economic activity and corporate earnings as key factors [4] - The bank also increases its allocation to US stocks slightly, while emphasizing the importance of diversification across major regions, particularly favoring Chinese stocks due to stimulus measures [4] - Standard Chartered lowers its stance on gold to a core holding, anticipating a period of consolidation, while still finding high-quality bonds attractive in the current yield environment [4] Group 3: OCBC Insights - OCBC highlights that the current weakness of the US dollar is influenced by trade policies, geopolitical factors, and global capital flows, rather than solely by interest rate cuts [5] - The bank advocates for a dynamic asset allocation strategy that increases exposure to safe-haven assets like gold and yen, while also focusing on currencies and equities driven by internal demand in Asia [5] - OCBC notes that some companies are shifting production to ASEAN countries, indicating a transition from simple exports to building local supply and industrial chains [5]

Core Viewpoint - The total scale of public funds in China has surpassed 33 trillion yuan, reflecting a significant growth driven by policy benefits, product innovation, and increasing demand for wealth management among residents [2][4][10]. Group 1: Growth of Public Fund Scale - As of April 2024, the total scale of public funds reached 33.12 trillion yuan, marking a historic high and the seventh increase since the beginning of 2024 [2][4]. - The growth in public fund scale is attributed to multiple factors, including the deepening of capital market reforms and the high-quality development of the industry, which has enhanced investor confidence [4][5]. - The increase in public fund scale indicates a shift in investor behavior towards diversified asset allocation, with public funds becoming a key tool for wealth management [4][8]. Group 2: Factors Driving Growth - The public fund scale has increased by 5 trillion yuan in 2024, showcasing its advantages over other asset management forms like bank wealth management and insurance [8][9]. - Key drivers of this growth include the release of policy dividends, product innovation, and changes in investor behavior, suggesting a sustainable growth trend [8][9]. - The demand for asset preservation and appreciation has intensified, with public funds offering a transparent and professionally managed investment option [4][6]. Group 3: Types of Funds and Investor Behavior - The growth of public funds is characterized by a rare simultaneous increase in money market funds, bond funds, and equity funds, indicating a diversification in investor asset allocation [14][16]. - In April, money market funds grew by 664.8 billion yuan, bond funds by 140.2 billion yuan, and equity funds by 112 billion yuan, with equity funds reaching a record high of 4.58 trillion yuan [14][17]. - The simultaneous growth of these fund types reflects enhanced market confidence and a shift in investor preferences towards balanced risk and return [14][19]. Group 4: Future Development and Market Trends - The public fund market in China has significant growth potential, driven by increasing resident wealth, the entry of long-term funds like pensions, and ongoing product innovation [11][12]. - The industry is expected to transition from a focus on scale expansion to quality-driven growth, with an emphasis on structural growth and globalization [12][20]. - Future trends indicate a diversification in fund types, with a focus on low-volatility products and asset allocation strategies supported by regulatory initiatives [27][29].

Core Viewpoint - Multiple foreign institutions express optimism about the value of asset allocation in China, citing improved corporate earnings prospects and relatively low asset valuations as factors enhancing the long-term attractiveness of Chinese assets to global investors [1]. Group 1: Stock Market Outlook - Morgan Stanley has raised its target index level for Chinese stocks due to structural improvements driven by shareholder returns and recent earnings [3]. - The reasons for increasing China's weight in portfolios remain valid, including a rebound in equity return rates and an upward shift in valuation ranges, particularly in offshore stock markets [4]. - Goldman Sachs maintains an "overweight" stance on Chinese stocks, attributing this to the strengthening of the RMB against the USD, which is expected to enhance the preference for RMB-denominated assets and improve corporate earnings prospects [5]. Group 2: Sector Performance - Non-essential consumer goods, real estate, and diversified financial stocks (brokerages) typically outperform the market during periods of RMB appreciation, while defensive stocks tend to lag [6]. Group 3: Market Opening and Regulatory Environment - The Chinese capital market continues to open steadily, creating a favorable ecosystem for investment through institutional reforms [8]. - The China Securities Regulatory Commission (CSRC) aims to enhance the transparency and predictability of regulations, improve communication mechanisms with international investors, and optimize arrangements for qualified foreign investors [9]. - The CSRC will focus on systemic openness, strengthening the coordination of stock, bond, and futures market openings, and increasing the supply of internationalized futures and options products [10]. - Enhanced bilateral and multilateral cross-border regulatory cooperation is also a priority, with a commitment to participating in the formulation of international standards and rules [11].

上天天基金APP搜索【777】注册即可 领98元券包 ， 优选创新药基金10元起投！限量发放！ 先到先得！ 今年以来，国产创新药行业出现重大价值重估。数据显示，截至6月6日，年内万得创新药指 数大涨逾20%，港股创新药指数更是涨超50%。 国产创新药是否迎来了"DeepSeek时刻"？国产创新药目前处于什么阶段，黄金投资周期来了 吗？创新药行业的竞争格局如何？未来还将面临哪些挑战？对此， 中国基金报记者采访了景 顺长城医疗产业基金经理乔海英、广发证券医药生物首席分析师罗佳荣、富国医药创新基金 经理赵伟、平安基金医药精选基金经理周思聪、财通资管创新医药混合基金经理易小金、开 源证券医药首席分析师余汝意 ，共同把脉国产创新药行业市场的投资机会和挑战。 周思聪： 2025年是中国创新药行业的"三个元年"——收入放量元年、盈利跨越元年和估值抬 升元年，行业有望迎来系统性投资机会。短期来看，2025年有望成为创新药企业收入集体放 量的起点。中期来看，2025年至2028年，中国创新药企业或成批步入盈利周期，2025年行 业有望开始集体跨越盈利的鸿沟。长期来看，2025年或成为中国创新药估值系统性提升的起 点。商业保险的 ...